• Morin: Mechanism, Evidence, and Research Workflow

  2026-08-22

  Morin is a natural flavonoid with the systematic name 2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one. Its research value combines antioxidant and inflammation-related pathway studies, reported inhibition of adenosine 5′-monophosphate deaminase, and fluorescent metal-ion detection.

• Methoxy-X04 Reveals Exercise-Linked Aβ Clearance

  2026-08-21

  Methoxy-X04 is a brain-permeable fluorescent amyloid beta probe for mapping plaques, oligomers, and cerebrovascular deposits in Alzheimer’s disease models. This article connects its assay logic to new evidence that muscle-derived extracellular vesicles enhance microglial amyloid clearance after exercise.

• Allosteric PDK4 Inhibitors for Metabolic Disease

  2026-08-20

  Jeon and colleagues developed an anthraquinone-derived series of allosteric pyruvate dehydrogenase kinase 4 inhibitors and identified compound 8c as a potent biochemical lead. The study connects PDK4 inhibition with improved glucose tolerance, reduced allergic responses, and anticancer activity in preclinical models while highlighting metabolic stability, pharmacokinetics, and docking as key development considerations.

• Exercise, EVs, and Amyloid Clearance in AD Mice

  2026-08-20

  A 2026 Nature Aging study identifies skeletal muscle-derived extracellular vesicles as a mediator of exercise-related cognitive benefit in Alzheimer’s disease mice. The work connects swimming exercise, miR-378a-3p cargo, disease-associated microglia, lipid metabolism, and amyloid-beta plaque clearance, suggesting a mechanistically defined exercise-mimicking strategy.

• AMPK–SQSTM1 Feedback Under Metabolic Stress

  2026-08-19

  A 2024 Autophagy study identifies a double-positive feedback loop between AMPK and SQSTM1/p62 that couples energy-stress adaptation to NRF2-dependent antioxidant defense. The work clarifies how lysosomal signaling, p62 phosphorylation, and metabolic context may help explain adaptation in STK11/LKB1- and KEAP1-altered lung cancer.

• JSH-23: Mechanism and NF-κB Inhibition

  2026-08-19

  JSH-23 is a small-molecule NF-κB inhibitor that suppresses p65 nuclear localization and DNA binding without blocking IκB degradation. Evidence from macrophage, airway epithelial, and cisplatin-induced acute kidney injury model studies supports its use as a mechanistic research tool, while also showing that pathway dependence varies by biological context.

• Methotrexate: Applied Folate Antagonist Workflows

  2026-08-18

  Build reproducible Methotrexate assays for DHFR inhibition, immune-cell proliferation, apoptosis, and inflammation research. A biomimetic chromatography comparison adds a practical decision framework for separating cell-based potency from membrane-partitioning and pulmonary-permeability questions.

• Parathyroid hormone (1-34) (human) in CKD Models

  2026-08-18

  Parathyroid hormone (1-34) (human) provides a defined way to activate PTH receptor signaling while connecting calcium biology with CKD-associated valvular calcification research. This guide translates the Foxp1–Notch findings into practical cell, co-culture, and in vivo workflows, with concentration, handling, and troubleshooting guidance.

• Firefly Luciferase mRNA: A Formulation-Aware Guide

  2026-08-17

  Firefly Luciferase mRNA is more than a bright reporter: its signal integrates transcript integrity, delivery, translation, and enzyme activity. This formulation-aware guide explains how ARCA capping, modified nucleotides, and lipid nanoparticle design influence assay interpretation.

• Phalloidin (B7678): F-Actin Workflow Guide

  2026-08-17

  Phalloidin (B7678) is a high-affinity F-actin probe for stabilizing and visualizing filamentous actin in fixed or permeabilized samples. It is useful for endpoint cytoskeleton analysis and morphology assays, but should not be used for live-cell imaging or experiments requiring reversible actin remodeling.

• Doxorubicin Hydrochloride: Applied Workflows

  2026-08-16

  Build reproducible cancer cytotoxicity and cardiotoxicity experiments with Doxorubicin hydrochloride, from concentration finding to mechanistic validation. The workflow also translates recent ATF4–CSE–H2S findings into practical assay choices without overstating preprint evidence.

• Amyloid Beta-peptide (25-35): Aβ25-35 Assay Logic

  2026-08-15

  Amyloid Beta-peptide (25-35) is more than a cytotoxicity reagent: it is a controlled perturbation for separating neuronal injury, oxidative stress, amyloid aggregation, and microglial signaling. This article translates the FLOT1–FOSL2–EphA2 study into practical assay decisions while defining the model’s strengths and limits.

• Auranofin: Applied Thioredoxin Reductase Workflows

  2026-08-14

  Auranofin converts thioredoxin reductase inhibition into practical redox, apoptosis, radiosensitization, antimicrobial, and metabolic-stress assays. This workflow-focused guide shows how to select concentrations, separate enzyme potency from cellular response, and connect redox phenotypes with the FOXO3/YAP metabolic findings reported in hepatocellular carcinoma.

• A40926 Workflows for Antibacterial Research

  2026-08-14

  A40926 supports mechanism-led antibacterial screening, MRSA research, and translational studies of glycopeptide activity. This workflow-focused guide connects MIC testing, resistant-pathogen profiling, and biosynthetic optimization while clearly separating evidence from practical recommendations.

• Protease Inhibitor Cocktail for Reliable Cell Assays

  2026-08-13

  This scenario-based guide explains how Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO), SKU K1008, can reduce proteolysis-related variability in protein endpoints associated with viability, proliferation, and cytotoxicity studies. It covers EDTA-sensitive workflows, dilution, DMSO controls, protein extraction, assay interpretation, and practical vendor-selection criteria.

7852 records 1/524 page Next 12345 下5页 Last page